rs10464870
|
|
|
0.700 |
GeneticVariation |
GWASDB |
Chromosome 7p11.2 (EGFR) variation influences glioma risk.
|
21531791 |
2011 |
rs10464870
|
|
G |
0.700 |
GeneticVariation |
GWASDB |
Genome-wide association study identifies five susceptibility loci for glioma.
|
19578367 |
2009 |
rs12544799
|
|
|
0.700 |
GeneticVariation |
GWASDB |
Chromosome 7p11.2 (EGFR) variation influences glioma risk.
|
21531791 |
2011 |
rs16904140
|
|
|
0.700 |
GeneticVariation |
GWASDB |
Chromosome 7p11.2 (EGFR) variation influences glioma risk.
|
21531791 |
2011 |
rs16904140
|
|
|
0.700 |
GeneticVariation |
GWASDB |
Genome-wide association study identifies five susceptibility loci for glioma.
|
19578367 |
2009 |
rs4295627
|
|
|
0.900 |
GeneticVariation |
BEFREE |
We identified five risk loci for glioma at 5p15.33 (rs2736100, TERT; P = 1.50 x 10(-17)), 8q24.21 (rs4295627, CCDC26; P = 2.34 x 10(-18)), 9p21.3 (rs4977756, CDKN2A-CDKN2B; P = 7.24 x 10(-15)), 20q13.33 (rs6010620, RTEL1; P = 2.52 x 10(-12)) and 11q23.3 (rs498872, PHLDB1; P = 1.07 x 10(-8)).
|
19578367 |
2009 |
rs4295627
|
|
G |
0.900 |
GeneticVariation |
GWASDB |
We identified five risk loci for glioma at 5p15.33 (rs2736100, TERT; P = 1.50 x 10(-17)), 8q24.21 (rs4295627, CCDC26; P = 2.34 x 10(-18)), 9p21.3 (rs4977756, CDKN2A-CDKN2B; P = 7.24 x 10(-15)), 20q13.33 (rs6010620, RTEL1; P = 2.52 x 10(-12)) and 11q23.3 (rs498872, PHLDB1; P = 1.07 x 10(-8)).
|
19578367 |
2009 |
rs4295627
|
|
|
0.900 |
GeneticVariation |
BEFREE |
Case-control analyses stratified into 4 molecular classes (defined by 1p-19q status, IDH mutation, and EGFR amplification) showed an association of rs4295627 and rs498872 with IDH-mutated gliomas (P < 10(-3)) and rs2736100 and rs6010620 with IDH wild-type gliomas (P < 10(-3) and P = .03).
|
23161787 |
2013 |
rs4295627
|
|
|
0.900 |
GeneticVariation |
BEFREE |
Thus, our meta-analysis suggests that the rs4295627 SNP is associated with an increased risk of glioma.
|
26505354 |
2015 |
rs4295627
|
|
|
0.900 |
GeneticVariation |
BEFREE |
Genome-wide association data have identified common genetic variants at 5p15.33 (rs2736100, TERT), 8q24.21 (rs4295627, CCDC26), 9p21.3 (rs4977756, CDKN2A-CDKN2B), 11q23.3 (rs498872, PHLDB1), and 20q13.33 (rs6010620, RTEL1) as determinants of glioma risk.
|
20462933 |
2010 |
rs4295627
|
|
|
0.900 |
GeneticVariation |
BEFREE |
In particular, both homozygous GG (P = 1.91 × 10, OR1 = 2.01) and heterozygous GT (P = 7.75 × 10, OR2 = 1.35) genotypes of rs4295627 were associated with glioma risk.
|
31277128 |
2019 |
rs4295627
|
|
|
0.900 |
GeneticVariation |
BEFREE |
Our group identified 5 risk loci for glioma susceptibility (TERT rs2736100, CCDC26 rs4295627, CDKN2A/CDKN2B rs4977756, RTEL1 rs6010620, and PHLDB1 rs498872).
|
20212223 |
2010 |
rs4295627
|
|
|
0.900 |
GeneticVariation |
BEFREE |
Specific single nucleotides polymorphisms (SNPs) rs4977756 (CDKN2A/B), rs6010620 (RTEL1), rs498872 (PHLDB1), rs2736100 (TERT), and rs4295627 (CCDC26) have been associated with glioma susceptibility and are potential risk biomarkers.
|
31721021 |
2020 |
rs4295627
|
|
|
0.900 |
GeneticVariation |
BEFREE |
The results of the present study clearly show that the G allele of the rs4295627 polymorphism significantly increases the risk of glioma.
|
29264887 |
2017 |
rs4295627
|
|
|
0.900 |
GeneticVariation |
BEFREE |
Three of the gene variants (rs4295627, a variant of CCDC26; rs4977756, a variant of CDKN2A and CDKN2B; and rs6010620, a variant of RTEL1) were statistically significantly associated with glioma risk in the present population.
|
21920947 |
2011 |
rs4295627
|
|
|
0.900 |
GeneticVariation |
BEFREE |
Genome-wide association studies have recently identified single-nucleotide polymorphisms (SNP) in five loci at 5p15.33 (rs2736100, TERT), 8q24.21 (rs4295627, CCDC26), 9p21.3 (rs4977756, CDKN2A/CDKN2B), 20q13.33 (rs6010620, RTEL1), and 11q23.3 (rs498872, PHLDB1) to be associated with glioma risk.
|
20847058 |
2010 |
rs4295627
|
|
|
0.900 |
GeneticVariation |
BEFREE |
Results showed that seven hot loci were all associated with increased risk of glioma (rs2736100, OR = 1.28, 95 %CI = 1.23-1.32; rs4295627, OR = 1.34, 95 %CI = 1.21-1.47; rs4977756, OR = 1.24, 95 %CI = 1.20-1.28; rs498872, OR = 1.24, 95 %CI = 1.15-1.33; rs6010620, OR = 1.29, 95 %CI = 1.24-1.35; rs11979158: OR = 1.18, 95 %CI = 1.10-1.25; rs2252586: OR = 1.18, 95 %CI = 1.10-1.25).
|
26243184 |
2016 |
rs4295627
|
|
G |
0.900 |
GeneticVariation |
GWASCAT |
We identified five risk loci for glioma at 5p15.33 (rs2736100, TERT; P = 1.50 x 10(-17)), 8q24.21 (rs4295627, CCDC26; P = 2.34 x 10(-18)), 9p21.3 (rs4977756, CDKN2A-CDKN2B; P = 7.24 x 10(-15)), 20q13.33 (rs6010620, RTEL1; P = 2.52 x 10(-12)) and 11q23.3 (rs498872, PHLDB1; P = 1.07 x 10(-8)).
|
19578367 |
2009 |
rs4295627
|
|
|
0.900 |
GeneticVariation |
GWASCAT |
Chromosome 7p11.2 (EGFR) variation influences glioma risk.
|
21531791 |
2011 |
rs4295627
|
|
|
0.900 |
GeneticVariation |
GWASDB |
Chromosome 7p11.2 (EGFR) variation influences glioma risk.
|
21531791 |
2011 |
rs4636162
|
|
|
0.700 |
GeneticVariation |
GWASDB |
Chromosome 7p11.2 (EGFR) variation influences glioma risk.
|
21531791 |
2011 |
rs55705857
|
|
|
0.760 |
GeneticVariation |
BEFREE |
IDH1/2 mutated glioma has been associated with a germline risk variant, the rs55705857 G allele.
|
30823903 |
2019 |
rs55705857
|
|
|
0.760 |
GeneticVariation |
BEFREE |
We also adjusted for the recently discovered 8q24 glioma risk locus rs55705857 G allele.
|
23361564 |
2013 |
rs55705857
|
|
G |
0.760 |
GeneticVariation |
GWASCAT |
Genome-wide association study identifies multiple susceptibility loci for glioma.
|
26424050 |
2015 |
rs55705857
|
|
|
0.760 |
GeneticVariation |
BEFREE |
Of the 6 variants located in 8q24, 2 have strong significant associations with the risk of glioma, including rs4295627 (P = .003, odds ratio [OR] = 1.21), rs55705857 (P = 2.31 × 10, OR = 3.54).
|
31277128 |
2019 |